Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10
- 30 October 2013
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (2) , 691-698
Abstract
Background There is the potential to use replication-competent oncolytic viruses to treat cancer. We evaluated the efficacy of HF10, a herpes simplex virus type 1 (HSV-1) mutant, in combination with...Keywords
This publication has 47 references indexed in Scilit:
- Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancerCancer Gene Therapy, 2011
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancerCancer Gene Therapy, 2010
- Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene TherapyCurrent Gene Therapy, 2008
- Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10Journal of Dermatological Science, 2008
- Changes in pancreatic cancer mortality, period patterns, and birth cohort patterns in Japan: analysis of mortality data in the period 1968–2002Environmental Health and Preventive Medicine, 2008
- Erlotinib in cancer treatmentAnnals of Oncology, 2007
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast CancerAnnals of Surgical Oncology, 2006
- Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor modelCurrent Oncology Reports, 2005
- Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10Journal of Surgical Oncology, 2003